MA46228A - Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll - Google Patents
Inhibiteurs bicycliques fusionnés de l'interaction ménine-mllInfo
- Publication number
- MA46228A MA46228A MA046228A MA46228A MA46228A MA 46228 A MA46228 A MA 46228A MA 046228 A MA046228 A MA 046228A MA 46228 A MA46228 A MA 46228A MA 46228 A MA46228 A MA 46228A
- Authority
- MA
- Morocco
- Prior art keywords
- menin
- mll interaction
- bicyclic inhibitors
- fusion
- fusion bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394291P | 2016-09-14 | 2016-09-14 | |
| EP16192424 | 2016-10-05 | ||
| EP17180228 | 2017-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46228A true MA46228A (fr) | 2019-07-24 |
Family
ID=59901513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046228A MA46228A (fr) | 2016-09-14 | 2017-09-13 | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10611778B2 (fr) |
| EP (1) | EP3512858B1 (fr) |
| JP (1) | JP7033141B2 (fr) |
| KR (1) | KR102493364B1 (fr) |
| CN (1) | CN109715634B (fr) |
| AU (1) | AU2017326485B2 (fr) |
| BR (1) | BR112019004764A2 (fr) |
| CA (1) | CA3033020A1 (fr) |
| ES (1) | ES2966316T3 (fr) |
| IL (1) | IL265231B (fr) |
| MA (1) | MA46228A (fr) |
| MX (1) | MX2019002959A (fr) |
| TW (1) | TWI753016B (fr) |
| WO (1) | WO2018050684A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (fr) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| MX2018011105A (es) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Inhibidores sustituidos de menina-mll y metodos de uso. |
| WO2017161002A1 (fr) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
| US11220517B2 (en) | 2016-09-14 | 2022-01-11 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| ES2901227T3 (es) | 2016-12-15 | 2022-03-21 | Janssen Pharmaceutica Nv | Inhibidores de azepano de la interacción menina-MLL |
| EP3601249A4 (fr) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN112105621B (zh) * | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
| CN112771055B (zh) * | 2018-08-08 | 2023-10-20 | 住友制药株式会社 | 光学活性桥接哌啶衍生物 |
| BR112021002090A8 (pt) | 2018-08-27 | 2022-12-06 | Sumitomo Dainippon Pharma Co Ltd | Derivado azabicíclico opticamente ativo |
| CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
| CN117321049A (zh) | 2021-05-08 | 2023-12-29 | 詹森药业有限公司 | 取代的螺环衍生物 |
| WO2022237627A1 (fr) | 2021-05-08 | 2022-11-17 | Janssen Pharmaceutica Nv | Dérivés spiro substitués |
| US20230250096A1 (en) | 2021-06-01 | 2023-08-10 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES |
| BR112023025436A2 (pt) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
| IL309359A (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexane-3-yl)- salt 6,2-diazaspiro[4.3]octan-6-yl)-4,2,1-triazin-6-yl)oxy) benzamide besylate for the treatment of diseases such as cancer |
| CN117561058A (zh) * | 2021-06-26 | 2024-02-13 | 塞迪拉治疗股份有限公司 | Cdk2抑制剂及其使用方法 |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| JP2005527502A (ja) | 2002-02-19 | 2005-09-15 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシン受容体の部分的および全アゴニスト |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2003299249B2 (en) * | 2002-12-23 | 2010-05-27 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| CA2566158A1 (fr) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Inhibiteurs de kinases en tant qu'agents therapeutiques |
| EP1856128A4 (fr) * | 2005-01-19 | 2009-12-23 | Merck & Co Inc | Inhibiteurs mitotiques de la kinesine |
| TWI389913B (zh) * | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| JP2011026305A (ja) * | 2009-06-24 | 2011-02-10 | Daiichi Sankyo Co Ltd | イミダゾールカルボニル化合物を含有する医薬組成物 |
| JP5792171B2 (ja) * | 2009-09-04 | 2015-10-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 白血病を治療するための組成物および方法 |
| US9029343B2 (en) | 2010-12-03 | 2015-05-12 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| WO2012075500A2 (fr) | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci |
| WO2014035140A2 (fr) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Composés et compositions pour la modulation de l'activité histone méthyltransférase |
| CN103664991B (zh) * | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
| PL2935222T3 (pl) | 2012-12-21 | 2019-02-28 | Epizyme Inc | Inhibitory PRMT5 i ich zastosowania |
| WO2014100730A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de la prmt5 contenant une dihydro- ou tétrahydro-isoquinoléine et leurs utilisations |
| WO2014100695A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| JP2016512514A (ja) | 2013-03-13 | 2016-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
| US20170119769A1 (en) * | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| EP3160477A4 (fr) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2016040330A1 (fr) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation |
| US10526341B2 (en) | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物 |
| EP3394064A1 (fr) | 2015-12-22 | 2018-10-31 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de l'interaction ménine-mll |
| MX2018011105A (es) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Inhibidores sustituidos de menina-mll y metodos de uso. |
| WO2017161002A1 (fr) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
| KR20190015275A (ko) | 2016-05-02 | 2019-02-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 메닌 억제제로서의 피페리딘 |
| WO2017207387A1 (fr) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1 |
| EP3805215A1 (fr) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibiteurs de l'interaction ménine-mll |
| WO2018024602A1 (fr) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro [4,4] nonanes |
| TWI738864B (zh) | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑 |
| US11220517B2 (en) * | 2016-09-14 | 2022-01-11 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| IL265028B (en) | 2016-09-16 | 2022-09-01 | Vitae Pharmaceuticals Llc | Inhibitors of the menin-mil interaction |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| EP3601249A4 (fr) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing |
-
2017
- 2017-09-13 TW TW106131464A patent/TWI753016B/zh not_active IP Right Cessation
- 2017-09-13 WO PCT/EP2017/073001 patent/WO2018050684A1/fr unknown
- 2017-09-13 JP JP2019535973A patent/JP7033141B2/ja active Active
- 2017-09-13 CN CN201780056197.2A patent/CN109715634B/zh active Active
- 2017-09-13 BR BR112019004764A patent/BR112019004764A2/pt active Search and Examination
- 2017-09-13 ES ES17768750T patent/ES2966316T3/es active Active
- 2017-09-13 US US16/331,579 patent/US10611778B2/en active Active
- 2017-09-13 MA MA046228A patent/MA46228A/fr unknown
- 2017-09-13 AU AU2017326485A patent/AU2017326485B2/en active Active
- 2017-09-13 MX MX2019002959A patent/MX2019002959A/es unknown
- 2017-09-13 CA CA3033020A patent/CA3033020A1/fr active Pending
- 2017-09-13 EP EP17768750.6A patent/EP3512858B1/fr active Active
- 2017-09-13 KR KR1020197007938A patent/KR102493364B1/ko active IP Right Grant
-
2019
- 2019-03-07 IL IL265231A patent/IL265231B/en active IP Right Grant
-
2020
- 2020-02-13 US US16/789,707 patent/US10975100B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2966316T3 (es) | 2024-04-19 |
| TWI753016B (zh) | 2022-01-21 |
| CN109715634B (zh) | 2022-09-27 |
| MX2019002959A (es) | 2019-07-04 |
| AU2017326485B2 (en) | 2021-04-22 |
| EP3512858A1 (fr) | 2019-07-24 |
| CA3033020A1 (fr) | 2018-03-22 |
| US10975100B2 (en) | 2021-04-13 |
| CN109715634A (zh) | 2019-05-03 |
| KR102493364B1 (ko) | 2023-01-27 |
| US20200172556A1 (en) | 2020-06-04 |
| US10611778B2 (en) | 2020-04-07 |
| US20190218230A1 (en) | 2019-07-18 |
| BR112019004764A2 (pt) | 2019-05-28 |
| TW201823249A (zh) | 2018-07-01 |
| IL265231B (en) | 2021-06-30 |
| AU2017326485A1 (en) | 2019-02-21 |
| WO2018050684A1 (fr) | 2018-03-22 |
| JP2019530745A (ja) | 2019-10-24 |
| IL265231A (en) | 2019-05-30 |
| KR20190046888A (ko) | 2019-05-07 |
| EP3512858B1 (fr) | 2023-11-08 |
| EP3512858C0 (fr) | 2023-11-08 |
| JP7033141B2 (ja) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46228A (fr) | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll | |
| IL283267A (en) | Inhibitors of menin–mll interaction | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| DK3507291T3 (da) | Kondenserede bicykliske sgc-stimulatorer | |
| MA46180A (fr) | Analogues de l'amyline | |
| MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
| DK3432872T3 (da) | Eflornithin til anvendelse til behandling af temozolomid tilbagevendende/refraktær anaplastisk astrocytom | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom | |
| ITUA20161599A1 (it) | Contenitore e procedimento per la realizzazione dello stesso | |
| IL262448B (en) | Disubstituted heterocyclic bicyclic compounds | |
| GB201720358D0 (en) | Fusion proteins for the detection of apoptosis | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
| FR3027492B1 (fr) | Egrappoir separateur-trieur de la vendange | |
| ITUA20163954A1 (it) | "integrazione dell'ordine logico" | |
| UA37280S (uk) | Інтер'єр зони відпочинку готелю | |
| UA37282S (uk) | Інтер'єр зони відпочинку готелю | |
| UA37278S (uk) | Інтер'єр зони відпочинку готелю | |
| ITUA20163709A1 (it) | "presentosa3d" | |
| FR3056541B1 (fr) | Douille cisaillable d'attelage ferroviaire | |
| IT201700025807A1 (it) | Procedimento per la realizzazione di mosaici | |
| FR3052524B1 (fr) | Joint d'etancheite | |
| FR3057727B1 (fr) | Compression optimisee d'entete ip-v6 | |
| ITUB20160364A1 (it) | Procedimento per la realizzazione di mosaici |